Aldeyra Therapeutics (NASDAQ:ALDX) Earns "Buy" Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX - Free Report) in a research report released on Monday morning,Benzinga reports. The firm currently has a $10.00 target price on the biotechnology company's stock. HC Wainwright also issued estimates for Aldeyra Therapeutics' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at $0.26 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $1.10 EPS.

Separately, BTIG Research decreased their target price on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Monday, April 7th.

Aldeyra Therapeutics Stock Down 1.3%

Shares of NASDAQ ALDX traded down $0.03 during trading on Monday, hitting $2.22. 704,068 shares of the company traded hands, compared to its average volume of 788,343. The business's fifty day moving average is $3.12 and its 200 day moving average is $4.63. Aldeyra Therapeutics has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The firm has a market capitalization of $132.97 million, a price-to-earnings ratio of -2.29 and a beta of 0.92. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08. Equities research analysts predict that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.

Insider Transactions at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the sale, the insider now directly owns 5,875,851 shares of the company's stock, valued at approximately $8,343,708.42. This represents a 36.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 9.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in Aldeyra Therapeutics by 14.4% in the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 2,822 shares in the last quarter. Geode Capital Management LLC boosted its stake in Aldeyra Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock valued at $5,588,000 after acquiring an additional 4,927 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Aldeyra Therapeutics by 1.9% in the fourth quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company's stock valued at $1,964,000 after acquiring an additional 7,348 shares during the last quarter. Intech Investment Management LLC boosted its stake in Aldeyra Therapeutics by 62.7% in the fourth quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company's stock valued at $119,000 after acquiring an additional 9,178 shares during the last quarter. Finally, Barclays PLC boosted its stake in Aldeyra Therapeutics by 14.9% in the fourth quarter. Barclays PLC now owns 75,330 shares of the biotechnology company's stock valued at $376,000 after acquiring an additional 9,769 shares during the last quarter. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.